Butane

Butane

SCHEMBL5162242

CCCC.O=C(OCCOC(=O)c1ccccc1)c1ccccc1

nearest known ligand 0.85

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.85
TDP1 Q9NUW8 5/20 0.70
TSHR P16473 6/20 0.58
ALDH1A1 P00352 3/20 0.58
ESR1 P03372 3/20 0.58
SLC6A2 P23975 2/20 0.58
CHRM1 P11229 1/20 0.58
KDR P35968 1/20 0.58
MAPK1 P28482 3/20 0.57
SLC6A3 Q01959 2/20 0.57
HIF1A Q16665 1/20 0.57
KMT2A Q03164 1/20 0.57
ESR2 Q92731 1/20 0.56
PKM P14618 1/20 0.55
CYP2D6 P10635 2/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
CYP1A2 P05177 2/20 0.55
CYP2C19 P33261 2/20 0.55
NR1H2 P55055 1/20 0.55
RNASEL Q05823 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL130761 0.92 LMNA (1.00) LMNATDP1TSHRALDH1A1ESR1
SCHEMBL7181498 0.92 LMNA (1.00) LMNATDP1TSHRALDH1A1ESR1
SCHEMBL137486 0.91 TDP1 (0.83) LMNATDP1TSHRALDH1A1ESR1
Butane SCHEMBL2548386 0.90 LMNA (0.76) LMNATDP1TSHRALDH1A1ESR1
Methane SCHEMBL28760616 0.90 LMNA (0.96) LMNATDP1TSHRALDH1A1ESR1
SCHEMBL28387455 0.90 LMNA (0.96) LMNATDP1TSHRALDH1A1ESR1
Methyl Alcohol SCHEMBL28069166 0.90 LMNA (0.96) LMNATDP1TSHRALDH1A1ESR1
SCHEMBL30886680 0.90 LMNA (0.96) LMNATDP1TSHRALDH1A1ESR1
SCHEMBL4465574 0.90 LMNA (0.96) LMNATDP1TSHRALDH1A1ESR1
Hydrochloric Acid SCHEMBL27605432 0.90 LMNA (0.96) LMNATDP1TSHRALDH1A1ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200339765-A1 Plastic Articles Containing Suspended Photochromic Dye Molecules 1-MATERIAL INC (CA) 2020-10-29 US claimed
EP-1748969-A1 METHOD OF ENHANCING THE APPEARANCE OF A SOILED POROUS SURFACE AND MAINTENANCE THEREOF JohnsonDiversey, Inc. (US) 2007-02-07 EP claimed
US-7071153-B2 Method of enhancing a soiled porous surface and maintenance thereof JOHNSONDIVERSEY, INC. (US) 2006-07-04 US claimed
WO-2005110946-A1 METHOD OF ENHANCING THE APPEARANCE OF A SOILED POROUS SURFACE AND MAINTENANCE THEREOF JOHNSONDIVERSEY, INC. (US) 2005-11-24 WO claimed
US-20050245420-A1 METHOD OF ENHANCING A SOILED POROUS SURFACE AND MAINTENANCE THEREOF JOHNSONDIVERSEY, INC. (US) 2005-11-03 US claimed
EP-0284302-A2 High solids PSA compounds BASF Aktiengesellschaft (DE) 1988-09-28 EP claimed
US-4767813-A High solids PSA Compounds POLYSAR FINANCIAL SERVICES S.A. (CH) 1988-08-30 US claimed
US-11015028-B2 Plastic articles containing suspended photochromic dye molecules ZHEJIANG JINGYI NEW MATERIAL TECHNOLOGY CO., LTD (CN) 2021-05-25 US disclosed
US-20200339765-A1 Plastic Articles Containing Suspended Photochromic Dye Molecules 1-MATERIAL INC (CA) 2020-10-29 US disclosed
US-10682361-B2 Sustained release bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction ALLERGAN, INC. (US) 2020-06-16 US disclosed
EP-3656375-A1 SUSTAINED RELEASE OF BIMATOPROST, BIMATOPROST ANALOGS, PROSTAMIDES AND PROSTAGLANDINS FOR FAT REDUCTION ALLERGAN, INC. (US) 2020-05-27 EP disclosed
EP-2983663-B1 SUSTAINED RELEASE OF BIMATOPROST, BIMATOPROST ANALOGS, PROSTAMIDES AND PROSTAGLANDINS FOR FAT REDUCTION ALLERGAN INC (US) 2020-01-22 EP disclosed
US-20160339039-A1 SUSTAINED RELEASE BIMATOPROST, BIMATOPROST ANALOGS, PROSTAMIDES AND PROSTAGLANDINS FOR FAT REDUCTION ALLERGAN INC (US) 2016-11-24 US disclosed
US-5409734-A Phase separation of a mixture comprising a homogeneous polymeric solution and a liquid suspension of light-polarizing particles HANKUK GLASS INDUSTRIES, INC. (KR) 1995-04-25 US disclosed
WO-1993014425-A1 LIGHT-POLARIZING LIQUID SUSPENSION, AND METHOD FOR MAKING THE LIQUID SUSPENSION HANKUK GLASS INDUSTRIES, INC. (KR) 1993-07-22 WO disclosed
WO-1993014426-A1 FILM FOR A LIGHT VALVE, AND METHOD FOR MANUFACTURING THE FILM HANKUK GLASS INDUSTRIES, INC. (KR) 1993-07-22 WO disclosed
EP-0551138-A1 Film for a light valve, and method for manufacturing the film HANKUK GLASS INDUSTRIES, INC. (KR) 1993-07-14 EP disclosed
EP-0551137-A1 Light-polarizing liquid suspension, and method for making the liquid suspension HANKUK GLASS INDUSTRIES, INC. (KR) 1993-07-14 EP disclosed
EP-0105994-B1 THERMOPLASTIC INKS FOR DECORATING PURPOSES Corning Glass Works (US) 1987-03-25 EP disclosed
EP-0105994-A1 Thermoplastic inks for decorating purposes Corning Glass Works (US) 1984-04-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10682361-B2 Sustained release bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction FABP4, PNLIP, PTGIS LMNA 2896/4885TDP1 2847/4885TSHR 2910/4885
US-20160339039-A1 SUSTAINED RELEASE BIMATOPROST, BIMATOPROST ANALOGS, PROSTAMIDES AND PROSTAGLANDINS FOR FAT REDUCTION FABP4, PNLIP, PTGIS LMNA 2896/4885TDP1 2847/4885TSHR 2910/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.